Company Profile
VRTX insider trades (13 months) →Today's multi-factor rank: 73 of 466 · see the ranking
Market and Valuation
Price & Market
52-Week Range
Volume
Valuation Multiples
Dividends
Valuation Context
P/E vs sector (indicative)
Loading historical OHLCV database...
| Date | Open | High | Low | Close | Volume |
|---|
Financial Statements TTM (Trailing 12 Months)
Income Statement
Margins
Per Share
Balance Sheet & Liquidity
Cash Flows
Profitability
Historical Evolution (Last 4 Years)
Income Statement
Balance Sheet
Cash Flow
EPS and Earnings Per Share
Key EPS Metrics
Growth and Margins
Per Share
Cash Flows (TTM)
EPS Surprise History - Last 4 Quarters
Actual vs. Analyst Estimates · Green = beat expectations · Red = missed
| Quarter | Period | Actual EPS | Estimated EPS | Difference | Surprise % | Currency |
|---|
Ownership Structure
Ownership Distribution
Shares & Short Interest
Governance Score (1=Best, 10=Worst)
Top Institutional Holders
Position Change: ▲ Increased · ▼ Reduced · = Unchanged
| Organization | Report Date | % Shares | No. Shares | Value (USD) | Change % |
|---|
Top Mutual Funds
Position Change: ▲ Increased ▼ Decreased = Unchanged
| Fund | Report Date | % Shares | No. Shares | Value (USD) | Change % |
|---|
Recent Insider Trades
| Executive / Insider | Title | Date | Action | Shares |
|---|
Options Chain
CALLS
| Strike | Last | Bid | Ask | Vol. | O.I. | IV |
|---|
PUTS
| Strike | Last | Bid | Ask | Vol. | O.I. | IV |
|---|
Sentiment Metrics
Expected move
Vertex Pharmaceuticals Incorporated (VRTX) SEC filings: 10-K, 10-Q and 8-K
Direct links to financial reports filed with the SEC.
| Type | Date | Official link |
|---|---|---|
| 8-K | 2026-09-01 | View filing ↗ |
| 10-Q | 2026-08-04 | View filing ↗ |
| 8-K | 2026-08-03 | View filing ↗ |
| 8-K | 2026-07-07 | View filing ↗ |
| S-8 POS | 2026-05-13 | View filing ↗ |
| 10-Q | 2026-05-05 | View filing ↗ |
| 8-K | 2026-05-04 | View filing ↗ |
| DEFA14A | 2026-04-29 | View filing ↗ |
| DEFA14A | 2026-04-02 | View filing ↗ |
| CORRESP | 2026-04-01 | View filing ↗ |
Company and Executive Profile
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
General Information
Key Executives
| Name | Title | Age | Total pay |
|---|---|---|---|
| Dr. Jeffrey Marc Leiden M.D., Ph.D. | Executive Chairman | 69 | - |
| Dr. Reshma Kewalramani FASN, M.D. | CEO, President & Director | 52 | 6.14M |
| Mr. Charles F. Wagner Jr. | Executive VP, COO & CFO | 57 | 2.99M |
| Mr. Amit K. Sachdev J.D. | Executive VP & Chief Patient and External Affairs Officer | 57 | 1.88M |
| Dr. Ourania Tatsis Ph.D. | Executive VP & Chief Product Affairs Officer | 55 | 2.07M |
| Dr. Carmen Bozic M.D. | Executive VP of Global Medicines Development & Medical Affairs and Chief Medical Officer | 62 | 2.27M |
| Ms. Kristen C. Ambrose CPA | Senior VP & Chief Accounting Officer | 48 | - |
| Dr. Mark Bunnage D.Phil | Executive VP & Chief Scientific Officer | 56 | - |
You have seen the engine room
Few finance sites let you get this far, and none we know of also shows you where its knowledge ends. If this way of working convinces you, the thing almost nobody catches in time can reach you by email: the big insider buys — executives and major shareholders putting in their own money — the same day they report them to the SEC, with the Form 4 linked. It takes three steps and none of them costs anything: create the account, confirm the email we send you, then switch the alert on in your profile (the icon at the top right). It starts off and it goes off again with the same click. Along the way all three are saved: your simulator portfolios, your personal portfolio and your Academy progress, synced across devices.